Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Net Margin (2016 - 2026)

Ocular Therapeutix has reported Net Margin over the past 13 years, most recently at 835.11% for Q1 2026.

  • For Q1 2026, Net Margin fell 24552.0% year-over-year to 835.11%; the TTM value through Mar 2026 reached 558.22%, down 22894.0%, while the annual FY2025 figure was 507.2%, 24815.0% down from the prior year.
  • Net Margin for Q1 2026 was 835.11% at Ocular Therapeutix, down from 492.45% in the prior quarter.
  • Over five years, Net Margin peaked at 142.09% in Q3 2023 and troughed at 835.11% in Q1 2026.
  • A 5-year average of 305.69% and a median of 214.88% in 2024 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: surged 15036bps in 2022 and later crashed -37472bps in 2025.
  • Year by year, Net Margin stood at 147.67% in 2022, then dropped by -4bps to 153.65% in 2023, then plummeted by -87bps to 286.92% in 2024, then crashed by -72bps to 492.45% in 2025, then crashed by -70bps to 835.11% in 2026.
  • Business Quant data shows Net Margin for OCUL at 835.11% in Q1 2026, 492.45% in Q4 2025, and 467.35% in Q3 2025.